Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 206 articles:
HTML format
Text format



Single Articles


    November 2018
  1. CHANDRASEKAR T, Dall'Era MA, Tilki D
    Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer.
    BJU Int. 2018;122:721-722.
    PubMed     Text format    


    October 2018
  2. ORCZYK C, Villers A, Rusinek H, Lepennec V, et al
    Prostate cancer heterogeneity: texture analysis score based on multiple MRI sequences for detection, stratification and selection of lesions at time of biopsy.
    BJU Int. 2018 Oct 30. doi: 10.1111/bju.14603.
    PubMed     Text format     Abstract available


  3. COLLINS A, Sundararajan V, Millar J, Burchell J, et al
    The trajectory of people who die from metastatic prostate cancer: A population-based study.
    BJU Int. 2018 Oct 29. doi: 10.1111/bju.14593.
    PubMed     Text format     Abstract available


  4. ONG WL, Yaxley JW, Millar JL
    Brachytherapy-based radiotherapy with androgen deprivation for management of high-risk prostate cancer - time to reverse the declining trend?
    BJU Int. 2018 Oct 19. doi: 10.1111/bju.14487.
    PubMed     Text format    


  5. VARMA M, Cochlin D, Delahunt B, Kynaston H, et al
    TNM clinical staging of prostate cancer: Issues and solutions.
    BJU Int. 2018 Oct 13. doi: 10.1111/bju.14589.
    PubMed     Text format     Abstract available


  6. GIELCHINSKY I, Chang J, Cusick T, Delprado W, et al
    Prostate Cancer in 432 men under the age of 50 years in the Prostate Specific Antigen era - a new outlook.
    BJU Int. 2018 Oct 10. doi: 10.1111/bju.14586.
    PubMed     Text format     Abstract available


  7. PINSKY PF, Miller E, Prorok P, Grubb R, et al
    Extended follow-up for prostate cancer incidence and mortality in the PLCO randomized cancer screening trial.
    BJU Int. 2018 Oct 5. doi: 10.1111/bju.14580.
    PubMed     Text format     Abstract available


  8. WARNER EW, Yip SM, Chi KN, Wyatt AW, et al
    DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
    BJU Int. 2018 Oct 3. doi: 10.1111/bju.14576.
    PubMed     Text format     Abstract available


  9. TORRES-ROMAN JS, Ruiz EF, Martinez-Herrera JF, Mendes Braga SF, et al
    Prostate Cancer Mortality rates in Peru and its geographic regions.
    BJU Int. 2018 Oct 3. doi: 10.1111/bju.14578.
    PubMed     Text format     Abstract available


    September 2018
  10. CAZZANIGA W, Garmo H, Robinson D, Holmberg L, et al
    Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.
    BJU Int. 2018 Sep 25. doi: 10.1111/bju.14563.
    PubMed     Text format     Abstract available


  11. KAYE DR, Qi J, Morgan TM, Linsell S, et al
    Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
    BJU Int. 2018 Sep 24. doi: 10.1111/bju.14554.
    PubMed     Text format     Abstract available


  12. VAN NIEUWENHOVE S, Saussez TP, Thiry S, Trefois P, et al
    Prospective comparison of a fast 1.5T biparametric to the 3.0T multi-parametric ESUR magnetic resonance imaging protocol as triage test for men at risk of prostate cancer.
    BJU Int. 2018 Sep 21. doi: 10.1111/bju.14538.
    PubMed     Text format     Abstract available


  13. STEUBER T, Tennstedt P, Macagno A, Athanasiou A, et al
    Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies.
    BJU Int. 2018 Sep 14. doi: 10.1111/bju.14540.
    PubMed     Text format     Abstract available


  14. VAN ROMPAY MI, Nickel JC, Ranganathan G, Kantoff PW, et al
    Impact of 5alpha-Reductase Inhibitors and alpha-Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality.
    BJU Int. 2018 Sep 14. doi: 10.1111/bju.14534.
    PubMed     Text format     Abstract available


  15. JAMES ND
    Prognostic and predictive models in hormone-sensitive prostate cancer.
    BJU Int. 2018;122:352-353.
    PubMed     Text format    


    August 2018
  16. WISSING M, Brimo F, Chevalier S, Scarlata E, et al
    Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14512.
    PubMed     Text format     Abstract available


  17. SHAH PH, Patel VR, Moreira DM, George AK, et al
    Implementation of Multiparametric Magnetic Resonance Imaging Technology for Evaluation of Patients with Suspicion for Prostate Cancer in the Clinical Practice Setting.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14515.
    PubMed     Text format     Abstract available


  18. JUNG JH, Risk MC, Goldfarb R, Reddy B, et al
    Primary cryotherapy for localised or locally advanced prostate cancer.
    BJU Int. 2018 Aug 16. doi: 10.1111/bju.14519.
    PubMed     Text format     Abstract available


  19. FENIOUX C, Louvet C, Charton E, Rozet F, et al
    Switch from Abiraterone + Prednisone to Abiraterone + Dexamethasone at asymptomatic PSA progression in metastatic castration-resistant prostate cancer (mCRPC) patients.
    BJU Int. 2018 Aug 11. doi: 10.1111/bju.14511.
    PubMed     Text format     Abstract available


  20. CARLES J, Pichler A, Korunkova H, Tomova A, et al
    Observational, multicenter study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
    BJU Int. 2018 Aug 11. doi: 10.1111/bju.14509.
    PubMed     Text format     Abstract available


  21. VAN LEEUWEN PJ, Donswijk M, Nandurkar R, Stricker P, et al
    68Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high-risk prostate cancer.
    BJU Int. 2018 Aug 3. doi: 10.1111/bju.14506.
    PubMed     Text format     Abstract available



  22. NICE Advice - Prolaris gene expression assay for assessing long-term risk of prostate cancer progression: (c) NICE (2016) Prolaris gene expression assay for assessing long-term risk of prostate cancer progression.
    BJU Int. 2018;122:173-180.
    PubMed     Text format    


  23. CULIG Z
    The way towards understanding possible multiple functions of AR V7 in prostate cancer.
    BJU Int. 2018;122:169.
    PubMed     Text format    


  24. THOMPSON JE, Stricker PD
    MRI improves active surveillance of prostate cancer however biopsy is still crucial.
    BJU Int. 2018;122:E1-E2.
    PubMed     Text format    


    July 2018
  25. SCAILTEUX LM, Rioux-Leclercq N, Vincendeau S, Balusson F, et al
    Use of 5alpha-reductase inhibitors for benign prostate hypertrophy and risk of high-grade prostate cancer: A French population-based study.
    BJU Int. 2018 Jul 19. doi: 10.1111/bju.14495.
    PubMed     Text format     Abstract available


  26. CHIONG E, Murphy DG, Akaza H, Buchan NC, et al
    Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference APCCC 2017.
    BJU Int. 2018 Jul 18. doi: 10.1111/bju.14489.
    PubMed     Text format     Abstract available


  27. PAK S, Park S, Kim M, Go H, et al
    The impact on oncologic outcomes after radical prostatectomy for prostate cancer of converting soft tissue margins at the apex and bladder neck from tumor positive to negative.
    BJU Int. 2018 Jul 6. doi: 10.1111/bju.14480.
    PubMed     Text format     Abstract available


  28. DAHRAN N, Szewczyk-Bieda M, Vinnicombe S, Fleming S, et al
    Periprostatic Fat Adipokines Expression Correlated with Prostate Cancer Aggressiveness in Men Undergoing Radical Prostatectomy for Clinically Localised Disease.
    BJU Int. 2018 Jul 3. doi: 10.1111/bju.14469.
    PubMed     Text format     Abstract available


    June 2018
  29. STONE NN, Stock RG
    Stage T3b prostate cancer diagnosed with seminal vesicle biopsy and treated by neoadjuvant hormone therapy, permanent brachytherapy and external beam irradiation.
    BJU Int. 2018 Jun 29. doi: 10.1111/bju.14464.
    PubMed     Text format     Abstract available


  30. ELLIOTT D, Hamdy FC, Leslie TA, Rosario D, et al
    Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation versus radical prostatectomy for unilateral localised prostate cancer.
    BJU Int. 2018 Jun 11. doi: 10.1111/bju.14432.
    PubMed     Text format     Abstract available


  31. KUANG AG, Nickel JC, Andriole GL, Castro-Santamaria R, et al
    Both acute and chronic inflammation are associated with lower perineural invasion in men with prostate cancer on repeat biopsy.
    BJU Int. 2018 Jun 6. doi: 10.1111/bju.14428.
    PubMed     Text format     Abstract available


    May 2018
  32. OTTI VC, Miller C, Powell RJ, Thomas RM, et al
    The diagnostic accuracy of multiparametric MRI prior to biopsy in the detection of prostate cancer.
    BJU Int. 2018 May 27. doi: 10.1111/bju.14420.
    PubMed     Text format     Abstract available


  33. BANCROFT EK, Saya S, Page EC, Myhill K, et al
    The psychosocial impact of undergoing prostate cancer screening for men with BRCA1/2 mutations.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14412.
    PubMed     Text format     Abstract available


  34. SZARVAS T, Sevcenco S, Modos O, Keresztes D, et al
    MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14415.
    PubMed     Text format     Abstract available


  35. KOVAC E, Vertosick EA, Sjoberg DD, Vickers AJ, et al
    Effects of Pathologic Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in men with Clinical Low-risk Prostate Cancer.
    BJU Int. 2018 May 26. doi: 10.1111/bju.14418.
    PubMed     Text format     Abstract available


  36. LOEB S, Taneja S, Walter D, Zweifach S, et al
    Crowd-Funding for Prostate Cancer and Breast Cancer.
    BJU Int. 2018 May 22. doi: 10.1111/bju.14408.
    PubMed     Text format     Abstract available


  37. ALI A, Hoyle A, Mistry H, Clarke NW, et al
    The importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
    BJU Int. 2018 May 19. doi: 10.1111/bju.14400.
    PubMed     Text format     Abstract available


  38. GANDAGLIA G, van den Bergh RCN, Tilki D, Fossati N, et al
    How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14391.
    PubMed     Text format     Abstract available


  39. ZHAO J, Sun G, Liao B, Zhang X, et al
    Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with de novo bone-metastatic prostate cancer.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14398.
    PubMed     Text format     Abstract available


  40. ISHIOKA J, Matsuoka Y, Uehara S, Yasuda Y, et al
    Computer-aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14397.
    PubMed     Text format     Abstract available


  41. HAJILI T, Ohlmann CH, Linxweiler J, Niklas C, et al
    Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: Results of a single-institution series with long-term follow up.
    BJU Int. 2018 May 17. doi: 10.1111/bju.14393.
    PubMed     Text format     Abstract available


  42. NEWTON RU, Jeffery E, Galvao DA, McIntyre C, et al
    Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen deprivation therapy.
    BJU Int. 2018 May 11. doi: 10.1111/bju.14384.
    PubMed     Text format     Abstract available


  43. HOFMAN MS, Murphy DG, Williams SG, Nzenza T, et al
    A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    BJU Int. 2018 May 3. doi: 10.1111/bju.14374.
    PubMed     Text format     Abstract available


  44. EMBERTON M
    Has tailored, tissue-selective tumour ablation in men with prostate cancer come of age?
    BJU Int. 2018;121:676-677.
    PubMed     Text format    


  45. VENTIMIGLIA E, Briganti A, Montorsi F
    Lymph node dissection during radical prostatectomy for prostate cancer: extending the template in the right patients without increasing complications.
    BJU Int. 2018;121:677-678.
    PubMed     Text format    


    April 2018
  46. BRIZMOHUN APPAYYA M, Adshead J, Ahmed HU, Allen C, et al
    National Implementation of multi-parametric MRI for prostate cancer detection - Recommendations from a UK consensus meeting.
    BJU Int. 2018 Apr 26. doi: 10.1111/bju.14361.
    PubMed     Text format     Abstract available


  47. SCHOOTS IG, Nieboer D, Giganti F, Moore CM, et al
    Is MRI-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.
    BJU Int. 2018 Apr 21. doi: 10.1111/bju.14358.
    PubMed     Text format     Abstract available


  48. MARTINI A, Gupta A, Lewis SC, Cumarasamy S, et al
    Development and Internal Validation of a Side Specific, Multiparametric MRI-based Nomogram for the Prediction of Extracapsular Extension of Prostate Cancer.
    BJU Int. 2018 Apr 19. doi: 10.1111/bju.14353.
    PubMed     Text format     Abstract available


  49. BRYANT RJ, Yang B, Philippou Y, Lam K, et al
    Does the introduction of prostate multiparametric MRI into active surveillance of localised prostate cancer improve patient re-classification?
    BJU Int. 2018 Apr 12. doi: 10.1111/bju.14248.
    PubMed     Text format     Abstract available


  50. CASH H, Steiner U, Heidenreich A, Klotz T, et al
    Intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration resistant prostate cancer (CRPC) - a phase III study (PRINCE).
    BJU Int. 2018 Apr 10. doi: 10.1111/bju.14239.
    PubMed     Text format     Abstract available


  51. LANCEE M, Tikkinen KAO, de Reijke TM, Kataja VV, et al
    Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer.
    BJU Int. 2018 Apr 7. doi: 10.1111/bju.14237.
    PubMed     Text format     Abstract available


  52. EBBINGE M, Berglund A, Varenhorst E, Hedlund PO, et al
    Clinical and Prognostic Significance of Changes in Haemoglobin Level During One Year of Androgen Deprivation Treatment for Hormone-Naive Bone Metastatic Prostate Cancer.
    BJU Int. 2018 Apr 2. doi: 10.1111/bju.14227.
    PubMed     Text format     Abstract available


  53. HARMOUCH SS, Berger AJ, Cole AP
    Low rates of bone density testing in prostate cancer survivors on androgen-deprivation therapy: where do we go from here?
    BJU Int. 2018;121:492-493.
    PubMed     Text format    


  54. KLOTZ L
    Prostate cancer prevention: proof is elusive.
    BJU Int. 2018;121:487-488.
    PubMed     Text format    


  55. LAING R, Uribe J, Uribe-Lewis S, Money-Kyrle J, et al
    LDR brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
    BJU Int. 2018 Apr 1. doi: 10.1111/bju.14223.
    PubMed     Text format     Abstract available


  56. BANDINI M, Marchioni M, Pompe RS, Tian Z, et al
    First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy.
    BJU Int. 2018;121:592-599.
    PubMed     Text format     Abstract available


    March 2018
  57. VATANDOUST S, Kichenadasse G, O'Callaghan M, Vincent AD, et al
    Localized prostate cancer in elderly men aged 80-89, findings from a population-based registry.
    BJU Int. 2018 Mar 30. doi: 10.1111/bju.14228.
    PubMed     Text format     Abstract available


  58. ANSMANN L, Winter N, Ernstmann N, Heidenreich A, et al
    Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW).
    BJU Int. 2018 Mar 30. doi: 10.1111/bju.14215.
    PubMed     Text format     Abstract available


  59. STATTIN P, Sandin F, Loeb S, Robinson D, et al
    Public online reporting from a nationwide population-based clinical prostate cancer register.
    BJU Int. 2018 Mar 25. doi: 10.1111/bju.14213.
    PubMed     Text format     Abstract available


  60. CHEN R, Dong X, Gleave M
    Molecular Model for Neuroendocrine Prostate Cancer Progression.
    BJU Int. 2018 Mar 22. doi: 10.1111/bju.14207.
    PubMed     Text format     Abstract available


  61. AUBERTIN K, Trinh VQ, Jermyn M, Baksic P, et al
    Mesoscopic characterization of prostate cancer using Raman spectroscopy: Potential for diagnostics and therapeutics.
    BJU Int. 2018 Mar 15. doi: 10.1111/bju.14199.
    PubMed     Text format     Abstract available


  62. RUSSO GI, Bier S, Hennenlotter J, Beger G, et al
    Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
    BJU Int. 2018 Mar 15. doi: 10.1111/bju.14200.
    PubMed     Text format     Abstract available


  63. VIDAL AC, Howard LE, de Hoedt A, Kane CJ, et al
    Obese Castration-Resistant Prostate Cancer Patients may be at a lower risk of all-cause mortality: Results from the SEARCH Database.
    BJU Int. 2018 Mar 9. doi: 10.1111/bju.14193.
    PubMed     Text format     Abstract available


  64. CHAO M, Ho H, Chan Y, Tan A, et al
    Prospective analysis of hydrogel spacer for prostate cancer patients undergoing radiotherapy.
    BJU Int. 2018 Mar 9. doi: 10.1111/bju.14192.
    PubMed     Text format     Abstract available


  65. COUTURE F, Tholomier C, Zorn KC
    Prostate cancer biochemical recurrence after salvage radiotherapy: first look into risk stratification and prognosis.
    BJU Int. 2018;121:320-321.
    PubMed     Text format    


  66. GHANEM S, Namdarian B, Challacombe B
    To drain or not to drain after robot-assisted radical prostatectomy? That is the question.
    BJU Int. 2018;121:321-322.
    PubMed     Text format    


  67. PALAYAPALAYAM GANAPATHI H, Onol F, Rogers T, Patel V, et al
    Nerve wrapping with biomaterials during radical prostatectomy to improve potency recovery.
    BJU Int. 2018;121:322-323.
    PubMed     Text format    


  68. SATHIANATHEN NJ, Christidis D, Konety BR, Lawrentschuk NL, et al
    Magnetic resonance imaging cognitive fusion biopsy - is near enough good enough?
    BJU Int. 2018;121:324-326.
    PubMed     Text format    


  69. PATEL VR, Sandri M, Grasso AAC, De Lorenzis E, et al
    A novel tool for predicting extracapsular extension during graded partial nerve sparing in radical prostatectomy.
    BJU Int. 2018;121:373-382.
    PubMed     Text format     Abstract available


  70. CHENAM A, Yuh B, Zhumkhawala A, Ruel N, et al
    Prospective randomised non-inferiority trial of pelvic drain placement vs no pelvic drain placement after robot-assisted radical prostatectomy.
    BJU Int. 2018;121:357-364.
    PubMed     Text format     Abstract available


  71. MAI Z, Xiao Y, Yan W, Zhou Y, et al
    Comparison of lesions detected and undetected by template-guided transperineal saturation prostate biopsy.
    BJU Int. 2018;121:415-420.
    PubMed     Text format     Abstract available


  72. PORPIGLIA F, Bertolo R, Fiori C, Manfredi M, et al
    Chitosan membranes applied on the prostatic neurovascular bundles after nerve-sparing robot-assisted radical prostatectomy: a phase II study.
    BJU Int. 2018;121:472-478.
    PubMed     Text format     Abstract available


    February 2018
  73. NASSAR ZD, Aref AT, Miladinovic D, Mah CY, et al
    Peri-Prostatic Adipose Tissue: The metabolic microenvironment of prostate cancer.
    BJU Int. 2018 Feb 20. doi: 10.1111/bju.14173.
    PubMed     Text format     Abstract available


  74. ALTOK M, Babaian K, Achim MF, Achim GC, et al
    Surgeon-Led Prostate Cancer Lymph Node Staging: Pathologic Outcomes Stratified by Robot-Assisted Dissection Templates and Patient Selection.
    BJU Int. 2018 Feb 15. doi: 10.1111/bju.14164.
    PubMed     Text format     Abstract available


  75. BOLTON EM, Lynch TH
    Are all gonadotropin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    BJU Int. 2018 Feb 13. doi: 10.1111/bju.14168.
    PubMed     Text format     Abstract available


  76. THURTLE D, Barrett T, Thankappan-Nair V, Koo B, et al
    Progression and treatment rates using an active surveillance protocol incorporating image guided baseline biopsies and multi-parametric MRI monitoring for men with favourable risk prostate cancer.
    BJU Int. 2018 Feb 13. doi: 10.1111/bju.14166.
    PubMed     Text format     Abstract available


  77. SOORIAKUMARAN P
    Surgery for oligometastatic prostate cancer: ready for prime time?
    BJU Int. 2018 Feb 12. doi: 10.1111/bju.14038.
    PubMed     Text format    


  78. WALLIS CJD, Satkunasivam R, Bhindi B
    Selecting patients for prostate cancer treatment: the role of comorbidity.
    BJU Int. 2018;121:164-165.
    PubMed     Text format    


  79. SOLIGO M, Sharma V, Karnes RJ
    Is it time for a more 'proactive' approach to metastatic prostate cancer?
    BJU Int. 2018;121:167-168.
    PubMed     Text format    


  80. BARNETT CL, Davenport MS, Montgomery JS, Wei JT, et al
    Cost-Effectiveness of Magnetic Resonance Imaging and Targeted Fusion Biopsy for Early Detection of Prostate Cancer.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14151.
    PubMed     Text format     Abstract available


  81. GILBERT DC, Duong T, Sydes M, Bara A, et al
    Transdermal Oestradiol as a method of androgen suppression for Prostate Cancer within the STAMPEDE Trial Platform.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14153.
    PubMed     Text format     Abstract available


  82. SONPAVDE G, Huang A, Wang L, Baser O, et al
    Taxane chemotherapy versus anti-androgen agents as first-line therapy for metastatic castration-resistant prostate cancer.
    BJU Int. 2018 Feb 1. doi: 10.1111/bju.14152.
    PubMed     Text format     Abstract available


  83. HEIDENREICH A, Pfister D
    Even 'low-dose' cabazitaxel requires careful and meticulous patient selection.
    BJU Int. 2018;121:163-164.
    PubMed     Text format    


  84. KENIGSBERG AP, Tamada T, Rosenkrantz AB, Llukani E, et al
    Multiparametric magnetic resonance imaging identifies significant apical prostate cancers.
    BJU Int. 2018;121:239-243.
    PubMed     Text format     Abstract available


  85. AUFFENBERG GB, Qi J, Gao Y, Miller DC, et al
    Evaluation of a needle disinfectant technique to reduce infection-related hospitalisation after transrectal prostate biopsy.
    BJU Int. 2018;121:232-238.
    PubMed     Text format     Abstract available


    January 2018
  86. RUTLEDGE AB, McLeod N, Mehan N, Regan TW, et al
    A clinician-centred program for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer.
    BJU Int. 2018 Jan 23. doi: 10.1111/bju.14144.
    PubMed     Text format     Abstract available


  87. ABDEL-RAHMAN O, Cheung WY
    External Validation Of The Prostascore Model Among Metastatic Hormone-Sensitive Prostate Cancer Patients Recruited In The CHAARTED Study.
    BJU Int. 2018 Jan 23. doi: 10.1111/bju.14138.
    PubMed     Text format     Abstract available


  88. LAZAREV S, Thompson MR, Stone NN, Stock RG, et al
    Low-Dose-Rate Brachytherapy for Prostate Cancer: Outcomes Beyond 10 Years of Follow-Up.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14122.
    PubMed     Text format     Abstract available


  89. SCHLUSSEL MARKOVIC E, Buckstein M, Stone NN, Stock RG, et al
    Outcomes and Toxicities in Intermediate-Risk Prostate Cancer Patients Treated with Brachytherapy Alone or Brachytherapy and Supplemental External Beam Radiation Therapy.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14128.
    PubMed     Text format     Abstract available


  90. FLETCHER SA, Berg S, Trinh QD
    The new frontier of prostate biopsy: determining the role of image-guidance in moving the needle.
    BJU Int. 2018;121:4-5.
    PubMed     Text format    


  91. STONE N
    Low dose rate prostate brachytherapy in younger men.
    BJU Int. 2018;121:2.
    PubMed     Text format    


  92. BORKOWETZ A, Hadaschik B, Platzek I, Toma M, et al
    Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naive patients.
    BJU Int. 2018;121:53-60.
    PubMed     Text format     Abstract available


  93. SHIN T, Smyth TB, Ukimura O, Ahmadi N, et al
    Diagnostic accuracy of a five-point Likert scoring system for magnetic resonance imaging (MRI) evaluated according to results of MRI/ultrasonography image-fusion targeted biopsy of the prostate.
    BJU Int. 2018;121:77-83.
    PubMed     Text format     Abstract available


  94. SU J, Zhu Q, Yuan L, Zhang Y, et al
    Transumbilical laparoendoscopic single-site radical prostatectomy and cystectomy with the aid of a transurethral port: a feasibility study.
    BJU Int. 2018;121:111-118.
    PubMed     Text format     Abstract available


    December 2017
  95. NANTON V, Appleton R, Loew J, Ahmed N, et al
    Men don't talk about their health, but will they CHAT? The potential of online holistic needs assessment in prostate cancer.
    BJU Int. 2017 Dec 27. doi: 10.1111/bju.14114.
    PubMed     Text format     Abstract available


  96. BRUINSMA SM, Zhang L, Roobol MJ, Bangma CH, et al
    The Movember Foundation's GAP3 cohort: A profile of the largest global prostate cancer active surveillance database to date.
    BJU Int. 2017 Dec 15. doi: 10.1111/bju.14106.
    PubMed     Text format     Abstract available


  97. VOSS J, Pal R, Ahmed S, Hannah M, et al
    Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
    BJU Int. 2017 Dec 14. doi: 10.1111/bju.14100.
    PubMed     Text format     Abstract available


  98. DRUSKIN SC, Tosoian JJ, Young A, Collica S, et al
    Incorporating Prostate Health Index Density, MRI, and Prior Negative Biopsy Status to Improve the Detection of Clinically Significant Prostate Cancer.
    BJU Int. 2017 Dec 12. doi: 10.1111/bju.14098.
    PubMed     Text format     Abstract available


  99. POON DM, Chan CK, Chan TW, Cheung FY, et al
    Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    BJU Int. 2017 Dec 6. doi: 10.1111/bju.14091.
    PubMed     Text format     Abstract available


  100. PORPIGLIA F, De Luca S
    Prostate cancer biomarkers: new scenarios in the multi-parametric magnetic resonance imaging era.
    BJU Int. 2017;120:745-746.
    PubMed     Text format    


  101. BULTIJNCK R, Van de Caveye I, Rammant E, Everaert S, et al
    Clinical Pathway improves Implementation of Evidence-based Strategies for the management of Androgen Deprivation Therapy-induced side effects in Prostate Cancer Patients.
    BJU Int. 2017 Dec 1. doi: 10.1111/bju.14086.
    PubMed     Text format     Abstract available


  102. BJURLIN MA, Taneja SS
    Novel risk stratification nomograms for counseling patients on the need for prostate biopsy.
    BJU Int. 2017;120:746-747.
    PubMed     Text format    


  103. DASGUPTA P
    NICE guidance and the BJUI.
    BJU Int. 2017;120:743.
    PubMed     Text format    


    November 2017
  104. KIRK PS, Borza T, Shahinian VB, Caram MEV, et al
    The implications of baseline bone health assessment at initiation of androgen deprivation therapy for prostate cancer.
    BJU Int. 2017 Nov 10. doi: 10.1111/bju.14075.
    PubMed     Text format     Abstract available


  105. SIRIWARDANA A, Thompson J, van Leeuwen PJ, Doig S, et al
    Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.
    BJU Int. 2017;120:673-681.
    PubMed     Text format     Abstract available


  106. BOEHM K, Leyh-Bannurah SR, Rosenbaum C, Brandi LS, et al
    Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy.
    BJU Int. 2017;120:666-672.
    PubMed     Text format     Abstract available


  107. HANSEN NL, Kesch C, Barrett T, Koo B, et al
    Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.
    BJU Int. 2017;120:631-638.
    PubMed     Text format     Abstract available


  108. YAXLEY AJ, Yaxley JW, Thangasamy IA, Ballard E, et al
    Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    BJU Int. 2017;120 Suppl 3:43-50.
    PubMed     Text format     Abstract available


  109. KINNEAR N, Smith R, Hennessey DB, Bolton D, et al
    Implementation rates of uro-oncology multidisciplinary meeting decisions.
    BJU Int. 2017;120 Suppl 3:15-20.
    PubMed     Text format     Abstract available


  110. LOEB S
    Educational intervention in prostate cancer.
    BJU Int. 2017;120.
    PubMed     Text format    


  111. CHALFIN HJ, Pienta KJ, Gorin MA
    Selection-free method reveals phenotypic diversity among prostate cancer circulating tumour cells.
    BJU Int. 2017;120.
    PubMed     Text format    


  112. STRATTON K
    Cystectomy for cT4 prostate cancer: the most radical treatment.
    BJU Int. 2017;120.
    PubMed     Text format    


  113. EPSTEIN JI
    Central pathology review of radical prostatectomy specimens does make a difference not only with grade.
    BJU Int. 2017;120.
    PubMed     Text format    


    October 2017
  114. GANDAGLIA G, Zaffuto E, Fossati N, Bandini M, et al
    Identifying the candidate for super extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14066.
    PubMed     Text format     Abstract available


  115. ILIC D, Evans SM, Allan CA, Jung JH, et al
    Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer: a Cochrane systematic review.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14062.
    PubMed     Text format     Abstract available


  116. HANSEN NL, Barrett T, Kesch C, Pepdjonovic L, et al
    Multicentre evaluation of Magnetic Resonance Imaging supported transperineal prostate biopsy in biopsy-naive men with suspicion of prostate cancer.
    BJU Int. 2017 Oct 11. doi: 10.1111/bju.14049.
    PubMed     Text format     Abstract available


  117. KLAASSEN Z, Murphy DG
    STAMPEDE-ing Towards Androgen Biosynthesis Inhibition for Treatment of High-Risk Hormone-Naive Prostate Cancer: Changing the LATITUDE.
    BJU Int. 2017 Oct 9. doi: 10.1111/bju.14050.
    PubMed     Text format     Abstract available


  118. FRADET V, Toren P, Nguile-Makao M, Lodde M, et al
    Prognostic value of urinary PCA3 during active surveillance of low-risk prostate cancer in patients receiving 5alpha-reductase inhibitors.
    BJU Int. 2017 Oct 3. doi: 10.1111/bju.14041.
    PubMed     Text format     Abstract available


  119. HAMMARSTEN J
    Anomalous observation with regard to prostate cancer in cancer research.
    BJU Int. 2017;120:456-457.
    PubMed     Text format    


  120. ALBERTS AR, Roobol MJ, Drost FH, van Leenders GJ, et al
    Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    BJU Int. 2017;120:511-519.
    PubMed     Text format     Abstract available


  121. LLUKANI E, Lepor H
    Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy.
    BJU Int. 2017;120:505-510.
    PubMed     Text format     Abstract available


  122. ZHAO S, Xia M, Tang J, Yan Y, et al
    Actual lowering effect of metabolic syndrome on serum prostate-specific antigen levels is partly concealed by enlarged prostate: results from a large-scale population-based study.
    BJU Int. 2017;120:482-489.
    PubMed     Text format     Abstract available


  123. LOEB S, Stork B, Gold HT, Stout NK, et al
    Tweet this: how advocacy for breast and prostate cancers stacks up on social media.
    BJU Int. 2017;120:461-463.
    PubMed     Text format    


    September 2017
  124. VAN STAM MA, van der Poel HG, van der Voort van Zyp JRN, Tillier CN, et al
    The accuracy of patients' perceptions of the risks associated with localized prostate cancer treatments.
    BJU Int. 2017 Sep 28. doi: 10.1111/bju.14034.
    PubMed     Text format     Abstract available


  125. BLANCHARD P, Davis JW, Frank SJ, Kim J, et al
    Quality of life following brachytherapy or bilateral nerve sparing robotic prostatectomy for prostate cancer: a prospective cohort.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14021.
    PubMed     Text format     Abstract available


  126. RULACH R, McKay S, Neilson S, White L, et al
    Real World Uptake, Safety Profile and Outcomes of Docetaxel in Newly Diagnosed Metastatic Prostate Cancer.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14025.
    PubMed     Text format     Abstract available


  127. BOSCO C, Wong C, Garmo H, Crawley D, et al
    Drugs for metabolic conditions and prostate cancer death in men on GnRH agonists.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14023.
    PubMed     Text format     Abstract available


  128. MARRA G, Dalmasso E, Angello M, Munegato S, et al
    Prostate Cancer Treatment in Renal Transplant Recipients: A Systematic Review.
    BJU Int. 2017 Sep 18. doi: 10.1111/bju.14018.
    PubMed     Text format     Abstract available


  129. POON Y, Pechlivanoglou P, Alibhai SMH, Naimark D, et al
    Systematic Review and Network Meta-Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen Deprivation Therapy to Reduce Risk of Fragility Fractures.
    BJU Int. 2017 Sep 18. doi: 10.1111/bju.14015.
    PubMed     Text format     Abstract available


  130. TAAFFE DR, Buffart LM, Newton RU, Spry N, et al
    Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    BJU Int. 2017 Sep 5. doi: 10.1111/bju.14008.
    PubMed     Text format     Abstract available


  131. LAWRENTSCHUK N, Corfield JM, Scott A
    Is choline-based PET imaging still relevant in recurrent prostate cancer?
    BJU Int. 2017;120:303-304.
    PubMed     Text format    


  132. STEURER S, Rico SD, Simon R, Minner S, et al
    High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.
    BJU Int. 2017;120:365-376.
    PubMed     Text format     Abstract available


  133. JACKSON WC, Desai NB, Abugharib AE, Tumati V, et al
    Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.
    BJU Int. 2017;120:351-357.
    PubMed     Text format     Abstract available


  134. KIM PJ, Park JY, Kim HG, Cho YM, et al
    Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma.
    BJU Int. 2017;120:343-350.
    PubMed     Text format     Abstract available


  135. SUARDI N, Montorsi F
    Salvage lymph node dissection: if yes, robotics?
    BJU Int. 2017;120:304-305.
    PubMed     Text format    


  136. FICARRA V, Novara G, Dasgupta P
    Robot-assisted vs open radical prostatectomy: the day after.
    BJU Int. 2017;120:308-309.
    PubMed     Text format    


    August 2017
  137. SCHELTEMA MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF, et al
    Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    BJU Int. 2017 Aug 21. doi: 10.1111/bju.13991.
    PubMed     Text format     Abstract available


  138. JANG WS, Kim MS, Jeong WS, Chang KD, et al
    Does robot-assisted radical prostatectomy benefit prostate cancer patients with bone oligometastases?
    BJU Int. 2017 Aug 21. doi: 10.1111/bju.13992.
    PubMed     Text format     Abstract available


  139. THOMPSON A, Beresford MJ, Sarmah P, Jefferies ER, et al
    Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post STAMPEDE world.
    BJU Int. 2017 Aug 19. doi: 10.1111/bju.13990.
    PubMed     Text format     Abstract available


  140. VAN DEN BOS W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, et al
    Focal irreversible electroporation as primary treatment for localized prostate cancer.
    BJU Int. 2017 Aug 10. doi: 10.1111/bju.13983.
    PubMed     Text format     Abstract available


  141. THALMANN GN, Nguyen DP
    Sentinel nodes in prostate cancer- are we chasing a ghost?
    BJU Int. 2017;120:161-162.
    PubMed     Text format    



  142. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: (c) NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int. 2017;120:168-184.
    PubMed     Text format    


  143. GORIN MA, Pomper MG, Pienta KJ, Rowe SP, et al
    Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer.
    BJU Int. 2017;120:160-161.
    PubMed     Text format    


  144. PAVLOVICH CP, Rocco B, Druskin SC, Davis JW, et al
    Urinary continence recovery after radical prostatectomy - anatomical/reconstructive and nerve-sparing techniques to improve outcomes.
    BJU Int. 2017;120:185-196.
    PubMed     Text format     Abstract available


  145. KADONO Y, Machioka K, Nakashima K, Iijima M, et al
    Changes in penile length after radical prostatectomy: investigation of the underlying anatomical mechanism.
    BJU Int. 2017;120:293-299.
    PubMed     Text format     Abstract available


  146. SUJENTHIRAN A, Charman SC, Parry M, Nossiter J, et al
    Quantifying severe urinary complications after radical prostatectomy: the development and validation of a surgical performance indicator using hospital administrative data.
    BJU Int. 2017;120:219-225.
    PubMed     Text format     Abstract available



  147. Abstracts of the 18th Asia-Pacific Prostate Cancer Conference 2017, Australia, 30 August-02 September 2017.
    BJU Int. 2017;120 Suppl 1:5-23.
    PubMed     Text format    


  148. MCGRATH S, Christidis D, Clarebrough E, Ingle R, et al
    Transperineal prostate biopsy - tips for analgesia.
    BJU Int. 2017;120:164-167.
    PubMed     Text format    


    July 2017
  149. ONG WL, Foroudi F, Evans S, Millar J, et al
    Large institutional variations in androgen deprivation therapy utilization with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
    BJU Int. 2017 Jul 27. doi: 10.1111/bju.13969.
    PubMed     Text format     Abstract available


  150. BASOURAKOS SP, Davis JW, Chapin BF, Ward JF, et al
    Baseline and Longitudinal Plasma Caveolin-1 Level as a Biomarker in Active Surveillance for Early Stage Prostate Cancer.
    BJU Int. 2017 Jul 15. doi: 10.1111/bju.13963.
    PubMed     Text format     Abstract available


  151. DESS RT, Hartman HE, Aghdam N, Jackson WC, et al
    Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer.
    BJU Int. 2017 Jul 15. doi: 10.1111/bju.13962.
    PubMed     Text format     Abstract available


  152. LANGLEY SEM, Soares R, Uribe J, Uribe-Lewis S, et al
    Long-term oncological outcomes and toxicity in 597 men </=60 years of age at time of low dose rate brachytherapy for localised prostate cancer.
    BJU Int. 2017 Jul 3. doi: 10.1111/bju.13946.
    PubMed     Text format     Abstract available


  153. BASOURAKOS SP, Hoffman K, Kim J
    Active surveillance in prostate cancer: new efforts, new voices, new hope.
    BJU Int. 2017;120:4-5.
    PubMed     Text format    


  154. SAYYID R, Perlis N, Ahmad A, Evans A, et al
    Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension.
    BJU Int. 2017;120:76-82.
    PubMed     Text format     Abstract available


  155. MOSCHINI M, Sharma V, Gandaglia G, Dell'Oglio P, et al
    Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.
    BJU Int. 2017;120:69-75.
    PubMed     Text format     Abstract available


  156. MAMAWALA MM, Rao K, Landis P, Epstein JI, et al
    Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance.
    BJU Int. 2017;120:25-31.
    PubMed     Text format     Abstract available


    June 2017
  157. DE BRUYCKER A, Lambert B, Claeys T, Delrue L, et al
    Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
    BJU Int. 2017 Jun 24. doi: 10.1111/bju.13938.
    PubMed     Text format     Abstract available


  158. SOORIAKUMARAN P
    Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone: a randomised controlled feasibility trial.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13925.
    PubMed     Text format     Abstract available


  159. TUMATI V, Jackson WC, Abugharib AE, Raj G, et al
    Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13926.
    PubMed     Text format     Abstract available


  160. VILLERS A, Flamand V, Arquimedes RC, Puech P, et al
    Robot-assisted partial prostatectomy for anterior prostate cancer: a step-by-step guide.
    BJU Int. 2017;119:968-974.
    PubMed     Text format     Abstract available


  161. DIOLOMBI ML, Epstein JI
    Metastatic potential to regional lymph nodes with Gleason score </=7, including tertiary pattern 5, at radical prostatectomy.
    BJU Int. 2017;119:872-878.
    PubMed     Text format     Abstract available


  162. CAVALLO JA, Tewari AK
    Somatic-autonomic neurorrhaphy for erectile function restoration after radical prostatectomy.
    BJU Int. 2017;119:816-818.
    PubMed     Text format    


    May 2017
  163. HEDDEN L, Wassersug R, Mahovlich S, Pollock P, et al
    Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners.
    BJU Int. 2017 May 17. doi: 10.1111/bju.13885.
    PubMed     Text format     Abstract available


  164. CHIU PKF, Alberts AR, Venderbos LDF, Bangma CH, et al
    Additional benefit of using a risk based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    BJU Int. 2017 May 12. doi: 10.1111/bju.13913.
    PubMed     Text format     Abstract available


  165. TOSOIAN JT, Chappidi MR, Bishoff JT, Freedland SJ, et al
    Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with NCCN Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13911.
    PubMed     Text format     Abstract available


  166. GREIMAN AK, Rosoff JS, Prasad SM
    Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13875.
    PubMed     Text format     Abstract available


  167. ZUMSTEG ZS, Zelefsky MJ, Woo KM, Spratt DE, et al
    Unification of favorable intermediate, unfavorable intermediate, and very high risk-stratification criteria for prostate cancer.
    BJU Int. 2017 May 2. doi: 10.1111/bju.13903.
    PubMed     Text format     Abstract available


  168. GANDAGLIA G, Fossati N, Dell'Oglio P, Montorsi F, et al
    Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?
    BJU Int. 2017;119:652-653.
    PubMed     Text format    


  169. TOSOIAN JJ, Chappidi M, Feng Z, Humphreys EB, et al
    Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    BJU Int. 2017;119:676-683.
    PubMed     Text format     Abstract available


  170. FRYDENBERG M
    Reliability of negative multiparametric MRI of the prostate: can we avoid the biopsy? Not yet!
    BJU Int. 2017;119:E9-E10.
    PubMed     Text format    


    April 2017
  171. PROTOPAPA E, van der Meulen J, Moore CM, Smith SC, et al
    Patient Reported Outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13896.
    PubMed     Text format     Abstract available


  172. PARSONS JK, Pierce JP, Mohler J, Paskett E, et al
    The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13890.
    PubMed     Text format     Abstract available


  173. CHIEN GW, Slezak JM, Harrison TN, Jung H, et al
    Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population.
    BJU Int. 2017 Apr 19. doi: 10.1111/bju.13843.
    PubMed     Text format     Abstract available


  174. CRAWLEY D, Garmo H, Rudman S, Stattin P, et al
    Association between Type 2 diabetes, curative treatment and survival in men with intermediate and high risk localised prostate cancer.
    BJU Int. 2017 Apr 18. doi: 10.1111/bju.13880.
    PubMed     Text format     Abstract available


  175. VIOLET JA, Hofman MS
    Prostate specific membrane antigen (PSMA) from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.
    BJU Int. 2017 Apr 5. doi: 10.1111/bju.13871.
    PubMed     Text format     Abstract available


  176. EMBERTON M
    An end to the phenomenon of 'upgrading' in early prostate cancer?
    BJU Int. 2017;119:506-507.
    PubMed     Text format    


  177. BAUER RM, Grabbert MT, Klehr B, Gebhartl P, et al
    36-month data for the AdVance XP(R) male sling: results of a prospective multicentre study.
    BJU Int. 2017;119:626-630.
    PubMed     Text format     Abstract available


  178. DAVIS JW, MacLennan G
    The BJUI's clinical trials initiative.
    BJU Int. 2017;119:503.
    PubMed     Text format    


    March 2017
  179. TELANG JM, Lane BR, Cher ML, Miller DC, et al
    Prostate cancer, family history, and eligibility for active surveillance: A systematic review of the literature.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13862.
    PubMed     Text format     Abstract available


  180. DIJKSTRA S, Govers TM, Hendriks RJ, Schalken JA, et al
    Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13861.
    PubMed     Text format     Abstract available


  181. GROGAN J, Gupta R, Mahon KL, Stricker PD, et al
    Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in radical prostatectomy patients with long-term follow up.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13857.
    PubMed     Text format     Abstract available


  182. HOWARD LE, Moreira D, De Hoedt A, Aronson WJ, et al
    Cut-points for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13856.
    PubMed     Text format     Abstract available


  183. CLEMENT-ZHAO A, Auvray M, Aboudagga H, Blanc-Durand F, et al
    Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13855.
    PubMed     Text format     Abstract available


  184. MACLENNAN S, Williamson PR, Bekema H, Campbell M, et al
    A core outcome set for localised prostate cancer effectiveness trials.
    BJU Int. 2017 Mar 27. doi: 10.1111/bju.13854.
    PubMed     Text format     Abstract available


  185. KANDASWAMY GV, Bennett A, Narahari K, Hughes O, et al
    Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate risk localised prostate cancer - results from a large contemporaneous cohort.
    BJU Int. 2017 Mar 20. doi: 10.1111/bju.13850.
    PubMed     Text format     Abstract available


  186. BALL MW, Harris KT, Schwen ZR, Mullins JK, et al
    Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series.
    BJU Int. 2017;119:444-448.
    PubMed     Text format     Abstract available


  187. GETTMAN MT
    Rethinking cancer surveillance with shared-care models and survivorship plans: the time is now!
    BJU Int. 2017;119:360-361.
    PubMed     Text format    


    February 2017
  188. FICARRA V, Crestani A, Rossanese M, Palumbo V, et al
    Urethral-fixation technique improves early urinary continence recovery in patients who undergo retropubic radical prostatectomy.
    BJU Int. 2017;119:245-253.
    PubMed     Text format     Abstract available


  189. MATHIEU R, Lucca I, Vartolomei MD, Mbeutcha A, et al
    Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.
    BJU Int. 2017;119:234-238.
    PubMed     Text format     Abstract available


  190. WASHINO S, Okochi T, Saito K, Konishi T, et al
    Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients.
    BJU Int. 2017;119:225-233.
    PubMed     Text format     Abstract available


    January 2017
  191. SANTOK GD, Abdel Raheem A, Kim LH, Chang K, et al
    Perioperative and short-term outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy stratified by gland size.
    BJU Int. 2017;119:135-141.
    PubMed     Text format     Abstract available


  192. ZARGAR H, van den Bergh R, Moon D, Lawrentschuk N, et al
    The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    BJU Int. 2017;119:110-115.
    PubMed     Text format     Abstract available


  193. DANNEMAN D, Drevin L, Delahunt B, Samaratunga H, et al
    Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012.
    BJU Int. 2017;119:50-56.
    PubMed     Text format     Abstract available


  194. PARK SY, Oh YT, Jung DC, Cho NH, et al
    Diffusion-weighted imaging predicts upgrading of Gleason score in biopsy-proven low grade prostate cancers.
    BJU Int. 2017;119:57-66.
    PubMed     Text format     Abstract available


  195. TOSOIAN JJ, Epstein JI
    Prognostic value of prostate biopsy grade: forever a product of sampling.
    BJU Int. 2017;119:5-7.
    PubMed     Text format    


  196. PERERA M, Katelaris N, Murphy DG, McGrath S, et al
    Prostate Imaging Reporting and Data System score of four or more: active surveillance no more.
    BJU Int. 2017;119:9-12.
    PubMed     Text format    


    October 2016
  197. MATARAZA JM, Gotwals P
    Recent advances in immuno-oncology and its application to urological cancers.
    BJU Int. 2016;118:506-14.
    PubMed     Text format     Abstract available


  198. DEVECI S, Gotto GT, Alex B, O'Brien K, et al
    A survey of patient expectations regarding sexual function following radical prostatectomy.
    BJU Int. 2016;118:641-5.
    PubMed     Text format     Abstract available


  199. WYSOCK JS, Mendhiratta N, Zattoni F, Meng X, et al
    Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.
    BJU Int. 2016;118:515-20.
    PubMed     Text format     Abstract available


  200. MURRAY NP, Aedo S, Reyes E, Orellana N, et al
    Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    BJU Int. 2016;118:556-62.
    PubMed     Text format     Abstract available


    June 2016
  201. ANDERSON CB, Tin AL, Sjoberg DD, Mulhall JP, et al
    Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  202. DE NUNZIO C, Presicce F, Lombardo R, Cancrini F, et al
    Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  203. DINH KT, Mahal BA, Ziehr DR, Muralidhar V, et al
    Risk of prostate cancer mortality in men with a history of prior cancer.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  204. WATSON E, Shinkins B, Frith E, Neal D, et al
    Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


    June 2015
  205. PARK J, Cho SY, Jeong SH, Lee SB, et al
    Low testosterone level is an independent risk factor for high-grade prostate cancer detection via biopsy.
    BJU Int. 2015 Jun 18. doi: 10.1111/bju.13206.
    PubMed     Text format     Abstract available


    May 2015
  206. CARLSSON S, Drevin L, Loeb S, Widmark A, et al
    Population-based study of long-term functional outcomes after prostate cancer treatment.
    BJU Int. 2015 May 8. doi: 10.1111/bju.13179.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: